BioUtah News
-
Fresenius Medical Care participates in three-way merger to create premier value-based kidney care provider in the U.S. – next important step in execution of growth strategy 2025
Fresenius Medical Care participates in three-way merger to create premier value-based kidney care provider in the U.S.
-
FACT SHEET: The Biden Administration’s Historic Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget
The Biden Administration’s Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget
-
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services
-
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
-
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
-
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue…
-
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
The total capital represents the largest seed financing for life science startups in Utah’s history
-
Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease
Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit.
-
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
-
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
-
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
FierceBiotech Special Report: The top 10 biotech IPOs of 2021
-
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
-
WATCH THE EXIM BANK & STEP GRANT FUNDS 101 WEBINAR REPLAY
WTC UTAH HAS A RECORD $1M+ TO ADMINISTER TO UTAH SMALL BUSINESSES. Learn from World Trade Center Utah, Meridian…
-
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
-
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA…
-
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of…
-
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one…
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with…
-
PolarityTE Announces $5.0 Million Registered Direct Offering
PolarityTE Announces $5.0 Million Registered Direct Offering
-
Senate HELP Committee Advances PREVENTS Pandemic Act
The Senate HELP Committee on Tuesday voted 20-2 to advance legislation, the PREVENTS Pandemic Act.
-
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company…
-
Tillis, Coons, Cotton, Hirono, and Scott Introduce Bipartisan Bill to Prevent the Chinese Communist Party from Stealing American Intellectual Property
Legislation would combat corrupt Chinese Courts from issuing “anti-suit injunctions” that prevent companies from challenging patent infringement from…
-
2022 Wilson Sonsini Entrepreneur and Investor Life Sciences Summit is a Raging Success
The 2022 Wilson Sonsini Entrepreneur and Investor Life Sciences Summit presented by BioUtah, BioHive and the PIVOT Center…
-
Xenter Selects New Headquarters in Draper
Xenter has leased 30,000 square feet to accommodate explosive growth in the new Irvine Office Park in Draper,…
-
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services…
-
IONIQ Sciences announces IP acquisition and License buyout
IONIQ Sciences announced that it has acquired from OT Acceptance, LLC certain intellectual property formerly licensed to the…
-
Metastatic Tumor Treatment with Novel GPX Embolic Device
Innovative Embolic Device by Fluidx Medical Used Successfully in a Variety of Complex Cancer Cases
-
Known Medicine Partners with Duke University to Predict Lung Cancer Response to Drug Treatments
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
-
Halia Therapeutics New Leadership Team
Halia Therapeutics New Leadership Team
-
BD Names William ‘Bill’ Brown to Board of Directors
BD Names William ‘Bill’ Brown to Board of Directors
-
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain,…
-
Merit Medical rises on Street-beating Q4, sets 2022 guidance
Merit Medical shares were up today on fourth-quarter results that topped the consensus forecast.
-
Civica to Manufacture and Distribute Affordable Insulin
Americans with diabetes will have access to more affordable insulins through a transparent, cost-plus model
-
BioUtah Legislative Update
BioUtah Legislative Update
-
MDMA Urgent Request: Medical Supplies for Ukraine Needed
MDMA Urgent Request: Medical Supplies for Ukraine Needed
-
ARUP Renames Consulting Team as ARUP Healthcare Advisory Services
ARUP Laboratories has renamed its expert team of healthcare consultants as ARUP Healthcare Advisory Services.
-
TRIA Transcatheter Biopolymer Heart Valve Shows Promise in Pilot Animal Study
Foldax announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™…
-
Rare Disease Week
BioUtah is pleased to recognize Rare Disease Day, designated as February 28. There are approximately 7,000 rare diseases,…
-
BD Appoints Shana Neal as Chief People Officer
BD announced that Shana Neal has been appointed chief people officer.
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8M Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial…
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
